Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Department of Dermatology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
J Clin Oncol. 2021 Apr 10;39(11):1243-1252. doi: 10.1200/JCO.20.02446. Epub 2021 Feb 18.
Although the prognosis of patients with thin primary cutaneous melanomas (T1, ≤ 1.0 mm) is generally excellent, some develop recurrence. We sought to develop and validate a model predicting recurrences in patients with thin melanomas.
A Dutch population-based cohort (n = 25,930, development set) and a cohort from an Australian melanoma treatment center (n = 2,968, validation set) were analyzed (median follow-up 6.7 and 12.0 years, respectively). Multivariable Cox models were generated for local, regional, and distant recurrence-free survival (RFS). Discrimination was assessed using Harrell's C-statistic for each outcome. Each nomogram performance was evaluated using calibration plots defining low-risk and high-risk groups as the lowest and top 5% of the nomogram risk score, respectively. The nomograms' C-statistics were compared with those of a model including the current American Joint Committee on Cancer staging parameters (T-stage and sentinel node status).
Local, regional, and distant recurrences were found in 209 (0.8%), 503 (1.9%), and 203 (0.8%) Dutch patients, respectively, and 23 (0.8%), 61 (2.1%), and 75 (2.5%) Australian patients, respectively. C-statistics of 0.79 (95% CI, 0.75 to 0.82) for local RFS, 0.77 (95% CI, 0.75 to 0.78) for regional RFS, and 0.80 (95% CI, 0.77 to 0.83) for distant RFS were obtained for the development model. External validation showed C-statistics of 0.80 (95% CI, 0.69 to 0.90), 0.76 (95% CI, 0.70 to 0.82), and 0.74 (95% CI, 0.69 to 0.80), respectively. Calibration plots showed a good match between predicted and observed rates. Using the nomogram, the C-statistic was increased by 9%-12% for the development cohort and by 11%-15% for the validation cohort, compared with a model including only T-stage and sentinel node status.
Most patients with thin melanomas have an excellent prognosis, but some develop recurrence. The presented nomograms can accurately identify a subgroup at high risk. An online calculator is available at www.melanomarisk.org.au.
尽管 T1 期(厚度≤1.0mm)原发性皮肤黑色素瘤患者的预后通常较好,但仍有部分患者会出现复发。我们旨在建立并验证预测 T1 期黑色素瘤患者复发的模型。
分析了荷兰人群队列(n=25930,开发集)和澳大利亚黑色素瘤治疗中心队列(n=2968,验证集)(分别中位随访 6.7 年和 12.0 年)。使用多变量 Cox 模型对局部、区域和远处无复发生存率(RFS)进行了分析。使用 Harrell 的 C 统计量评估每种结局的区分度。使用校准图将风险评分最低的和前 5%的患者分别定义为低风险组和高风险组,评估每个列线图的性能。比较了列线图的 C 统计量与包括当前美国癌症联合委员会分期参数(T 分期和前哨淋巴结状态)的模型。
荷兰队列分别有 209 例(0.8%)、503 例(1.9%)和 203 例(0.8%)患者发生局部、区域和远处复发,澳大利亚队列分别有 23 例(0.8%)、61 例(2.1%)和 75 例(2.5%)患者发生上述情况。开发模型中局部 RFS 的 C 统计量为 0.79(95%CI,0.75 至 0.82),区域 RFS 为 0.77(95%CI,0.75 至 0.78),远处 RFS 为 0.80(95%CI,0.77 至 0.83)。外部验证显示,C 统计量分别为 0.80(95%CI,0.69 至 0.90)、0.76(95%CI,0.70 至 0.82)和 0.74(95%CI,0.69 至 0.80)。校准图显示预测值与观察值之间具有良好的一致性。与仅包含 T 分期和前哨淋巴结状态的模型相比,使用列线图可使开发队列的 C 统计量增加 9%-12%,使验证队列的 C 统计量增加 11%-15%。
大多数 T1 期黑色素瘤患者的预后较好,但仍有部分患者会出现复发。本研究提供的列线图可以准确识别高风险亚组。一个在线计算器可在 www.melanomarisk.org.au 上获取。